My Treatment Approach Beyond the First-Line: Expert Insights on Evidence-Driven TKI Selection and Sequencing in Advanced GIST - Episode 9
Next-Generation Treatment Strategies for GIST: Evaluating Combination Therapies and Mutation-Specific Approaches
Experts discuss the preliminary results of the PEAK study on the combination of bezuclastinib and sunitinib in second-line gastrointestinal stromal tumors (GIST), its potential to address heterogeneous resistance mutations, and how mutation-specific, biomarker-driven approaches in ongoing trials like INSIGHT may shift the treatment paradigm compared with traditional line-of-therapy strategies.
Video content above is prompted by the following:
- The PEAK study is evaluating the combination of bezuclastinib plus sunitinib vs sunitinib alone in second-line GIST. Can you walk us though the preliminary results and comment on how might this combination approach address the challenge of heterogeneous resistance mutations we see after imatinib failure?
- How is this combination approach different from our current sequential TKI approach, and how might this combined targeting strategy address the challenge of heterogeneous resistance mutations we see after imatinib failure?
- What would you consider a clinically meaningful improvement over sunitinib monotherapy that would change your practice?
- Ongoing trials such as INSIGHT are taking a more targeted biomarker-driven approach by focusing on specific molecular subgroups. How might these mutation-specific approaches change our treatment paradigm compared with the traditional line-of-therapy approach?
Please feel free to highlight any other ongoing trials of note.
Related Content:
